secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001193125-25-014473
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace issues 2025 revenue guidance $92M-$96M; 3-year CAGR target 20%+
-------------------------------------------------------------------------

- 2025 revenue guidance $92M-$96M (15.5%-20.5% YoY growth); gross margin 73%-75%; total OpEx $92M-$95M.
- Three-year targets: 20%+ revenue CAGR, indication expansion to IGE/pediatric, AI tools, and cash flow breakeven.
- Post-approval trial: 82% median seizure reduction at 36 months (n=255); 42.5% seizure-free ≥6 months; 22% ≥1 year.
- NAUTILUS trial (IGE): 87 patients implanted; 1-yr follow-up due by March 2025; data lock Q2 2025; FDA submission H2 2025.
- Plans to release first AI-powered electrographic seizure classifier tool within RNS System PDMS in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000119312525014473/0001193125-25-014473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000119312525014473/d877194d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-014473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer